GlassScriptPhysician profile
Josephine E Aideloje
NPI 1790272243
$1,037.90
in general payments reported to CMS, 2019-2025
12 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.17 · 2022: $157 · 2023: $148 · 2024: $219 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $866.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $212.19 | 2023-2025 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $204.46 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $156.88 | 2022 | |
| Lundbeck LLC | $122.51 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $88.39 | 2024-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $68.56 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $66.01 | 2023 | Auvelity |
| Sage Therapeutics, LLC | $41.55 | 2025 | Zurzuvae |
| Abbvie INC. | $39.42 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.32 | 2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $13.28 | 2024 | Qelbree |
| Corium, LLC | $6.33 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josephine Aideloje listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.